Recognize an offer to leave behind
A clear offer lets you separate the assessment, the product and the pharmacy. Keep asking when those parts disappear behind a sales claim.
- Pause when there is no assessment to describe.
- Request the pharmacy’s actual name.
- Check what an approval or research claim really establishes.
Compare care with a transaction
The prescription
The rule reviewed for September 2026 makes dispensing prescription drugs without the required prescription a federal-law violation.
A prescription is the order a licensed prescriber issues for a medicine. Before considering a product, ask who evaluates the person seeking it. Ask how that person can raise a concern that was not on the first form.
The pharmacy
FDA’s online-pharmacy checklist identifies access to a licensed pharmacist and state pharmacy licensing as checks to make.
Ask for the dispensing pharmacy’s name, rather than only the name at the top of the website. Keep that answer for the state lookup. A website can describe a service without clearly saying which pharmacy fills the prescription.
Read research wording with the sales claims
FDA’s September 2026 record includes warnings to firms whose research-labeled products were nevertheless marketed for people to use as drugs.
“Research use only” means the label describes the substance as a research chemical, rather than medicine for personal treatment. A research disclaimer is a statement using words like these. If an offer uses that wording, ask where the care decision, prescription and pharmacy fit. A research disclaimer beside a treatment claim does not answer those questions.
Medicines in this group imitate a hormone called GLP-1. The hormone is involved in appetite as well as blood sugar.
In September 2026 consumer information, FDA cautions against research-labeled GLP-1 products marketed to people, citing uncertain quality and the potential for harm.
Telehealth means receiving care by phone or computer. A research-market offer is a product pitch, not that care process. The comparison is between a care process and a product pitch. Keep the distinction visible when a page blurs them together.
Check what a badge proves
Establishment registration records a business with FDA; drug listing records information about a product. Under the September 2026 rule, putting a business or drug on a register does not approve it or make selling the drug lawful.
FDA also says that a National Drug Code, or NDC, number is not proof that the agency approved the product.
An NDC is a product-identification code in a drug directory. Ask whether the offer is pointing to a product approval, a registration or a listing. Keep the exact wording so you can check the right record.
A compounded medicine is mixed or changed for an individual need.
FDA’s September 2026 advertising guidance identifies claims that a compounded medicine is FDA-approved, a generic version or clinically proven to match the approved drug as false or misleading.
For medicines, generic means a copy with FDA approval, based on a brand-name drug. It is not just another name for a cheaper custom preparation. Neither semaglutide (Ozempic, Wegovy) nor tirzepatide (Mounjaro, Zepbound) had an approved generic available for U.S. sale on November 3, 2026. Ask for the exact product if that word appears. Do not replace a missing answer with a guess based on the ingredient name.
Match the name with the record
The ingredients named semaglutide and tirzepatide appear in approved diabetes and weight treatments in the September 2026 record.
FDA’s September 2026 record describes fraudulent compounded semaglutide and tirzepatide products that named pharmacies which did not exist or did not make them.
Use the name you were given in the state pharmacy search. If the result does not match, ask for clarification before treating the label as settled evidence. A real name printed somewhere else is not a substitute for a matching record.
FDA directs readers away from a pharmacy when the state board’s license search has no listing for it.
Also read the payment and cancellation terms. A hurried decision is not required to make the comparison useful. Keep the unanswered question, close the offer if necessary and use the official source that answers that question directly.
Check the source record